Floatz Rating
B58/100
Confidence
Indicative
Sponsor
University of Chicago
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07294677CT.gov CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL | — | Recruiting | — | — | — |
NCT01094860CT.gov Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies | — | Completed | — | — | — |
NCT00006020CT.gov S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia | — | Completed | — | — | — |
NCT00004239CT.gov 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment | — | Terminated | — | — | — |
NCT00003837CT.gov 506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | — | Completed | — | — | — |
NCT00003635CT.gov 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents | — | Completed | — | — | — |
NCT00003545CT.gov 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nelarabine (this asset) | University of Chicago | P2 | B · 58 |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BB |
| Vincristine Sulfate | Inhye Ahn | P3 | BB |
| Daunomycin | Richard Stone, MD | P3 | BB |
| Nivestim | Hospital General de Mexico | P4 | BB |
| Mercaptopurine Anhydrous | Dana-Farber Cancer Institute | P3 | BB |
| Pegaspargase | Dana-Farber Cancer Institute | P3 | BB |
| Busulfanum | National Cancer Institute (NCI) | P4 | BB |
| Idarubicin | Affiliated Hospital of Nantong University | P3 | BB |
+42 more in the Leukemia cohort
Other indications for Nelarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Lymphoblastic Lymphoma | — | P3 | BB · 64 |
| T-Cell Acute Lymphoblastic Leukemia | — | P3 | B · 61 |
| Lymphoblastic Lymphoma | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nelarabine in Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nelarabine-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →